Navigation Links
Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Date:2/25/2009

payor acceptance of our products as safe and effective therapeutic products; our ability to maintain regulatory approvals to market and sell our products; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Cornerstone Therapeutics' Current Report on Form 8-K, as amended, filed with the Securities and Exchange Commission (the SEC) on November 5, 2008, in the section titled "Risk Factors of the Registrant" as set forth in Exhibit 99.3, and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispos
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
5. Pearl Therapeutics Secures $8 Million in Debt Financing
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Amicus Therapeutics Announces Change to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), ... technologies and products for advanced microarray diagnostics, today announced ... August 22 at 2:00 pm ET.  ... provide a brief review of SQI,s recent commercialization progress ... diagnostics industry veteran recently appointed to the Board of ...
(Date:8/18/2014)...   Sterne, Kessler, Goldstein & Fox P.L.L.C. , ... DC , announced today that it has filed ... with the U.S. Patent and Trademark Office (USPTO) on ... Inc. (Nasdaq: BRLI).  These IPR petitions aim to nullify ... Inc. These patents have been asserted against GeneDx in ...
(Date:8/18/2014)... (PRWEB) August 18, 2014 Global HIV ... pharma report announced by Reportstack. The rate of HIV infection ... on a declining note at a positive rate across the ... from 2.3 million in 2005 to 1.5 in 2013, with ... cause for such drastic changes in the infection rates has ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 8 Millstone Medical Outsourcing,announced today that the ... MA,to accommodate growing business with new and existing ... The new facility, located at,580 Commerce Drive, includes ... for advanced inspection services, ultrasonic cleaning,and sterile and ...
... PT. RICHMOND, Calif., Oct. 8 Transcept Pharmaceuticals,Inc., ... P. Soloway, Senior Vice President and Chief Financial ... Second Annual Hidden,Gems Conference in New York City ... Time., An audio webcast of the presentation ...
... J. Kern and Peter Ver ... Lee Among the Highlights, ... for optimizing patient outcomes is the topic,of multiple sessions at this ... 12-17 in,Washington, D.C., Radi Medical Systems, the first company to ...
Cached Biology Technology:Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity 2Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2Radi Medical Systems Announces Schedule for TCT 2008 2
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
(Date:8/20/2014)... past few years, Virginia Tech,s Wu Feng has built ... from the "Computing in the Cloud" program, and synergistically ... million award from the Air Force on "big computing" ... and the National Institutes of Health on "big data" ... the "parallel computing" aspects from each grant, he was ...
(Date:8/20/2014)... colony of honeybees grows to about 4,000 members, it ... the building of a special type of comb used ... experts from the Department of Neurobiology and Behaviour at ... the reproductive cycle of honeybee colonies. The results are ... of Nature . , Reproduction isn,t always a ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2
... 2011 - Tropical maize proves to be a valuable ... Belt maize. Most tropical maize varieties respond to the ... regions by flowering late. This delayed flowering response results ... hindering their incorporation into maize hybrids adapted to the ...
... Medical Center announced today that it is the first medical ... a cutting-edge biometric technology – to identify patients. Utilizing near ... through the veins in a person,s palm, the digital palm ... with the medical center,s electronic health record system. ...
... titanium dental implants could be improved. By studying the surface ... also at nano level, researchers at the University of Gothenburg; ... the healing time for patients. , "Increasing the active surface ... allows us to affect the body,s own biomechanics and speed ...
Cached Biology News:Unique gene combinations control tropical maize response to day lengths 2Patient Identification "In The Palm Of Your Hand" 2Patient Identification "In The Palm Of Your Hand" 3Healing times for dental implants could be cut 2
... MultiScribe Reverse Transcriptase is a recombinant ... transcriptase. MultiScribe Reverse Transcriptase is similar ... in its recommended usage. MuLV reverse ... polymerase that uses single-stranded RNA as ...
... determination of digitonin and digoxin. Physical form: Lyophilized ... and 0.06% NaCl Preparation Note: Sodium iodide ... Res. Commun., 19, 755 (1965). Unit Definition: ... phosphorus from ATP per min at pH 7.4 ...
... protease from human rhinovirus (HRV 3C) is ... line of restriction grade proteases. The recombinant ... protein, which recognizes the same cleavage site ... 22 KDa size of the protease, optimal ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Biology Products: